HIKAL Hikal Q1 FY26 results (Apr–Jun 2025) and concall
Hikal reported a challenging Q1 FY26, primarily due to deferred shipments in its Pharmaceutical Business following a US FDA OAI status at its Bangalore facility, leading to a significant drop in revenue and EBITDA margins. The Crop Protection business remained flat amidst pricing pressures. Despite the slow start, management expressed confidence in resolving the regulatory issues and reiterated its full-year guidance, anticipating a strong recovery in the second half of FY26, driven by increased offtakes and new product commercialization.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 453 | 448 | 552 | 380 |
| EBITDA | 75 | 72 | 123 | 25 |
| Net profit | 18 | 17 | 50 | -22 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
